Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Journal of Nephrology|January 27, 2024
Outcome of atypical hemolytic uremic syndrome: role of triggers and complement abnormalities in the response to C5 inhibitionGianluigi Ardissino, Donata Cresseri, Maria Cristina Mancuso, et al.
Frontiers in Medicine|August 28, 2023
Impact of hyperparathyroidism and its different subtypes on long term graft outcome: a single Transplant Center cohort studyPaolo Molinari, Anna Regalia, Alessandro Leoni, et al.
Frontiers in Medicine|February 14, 2024
Corrigendum: Impact of hyperparathyroidism and its different subtypes on long term graft outcome: a single Transplant Center cohort studyPaolo Molinari, Anna Regalia, Alessandro Leoni, et al.
Vaccines|July 27, 2022
How Vaccinations Changed the Outcome of COVID-19 Infections in Kidney Transplant Patients: Single-Center ExperienceMariarosaria Campise, Carlo Maria Alfieri, Matteo Benedetti, et al.
Clinical Immunology (Orlando, Fla.)|May 11, 2024
Sequential administration of anti-complement component C5 eculizumab and type-2 anti-CD20 obinutuzumab for the treatment of early antibody-mediated rejection after kidney transplantation: A proof of conceptEvaldo Favi, Donata Cresseri, Marta Perego, et al.
Kidney International Reports|June 25, 2021
Risk of Atypical HUS Among Family Members of Patients Carrying Complement Regulatory Gene AbnormalityGianluigi Ardissino, Selena Longhi, Luigi Porcaro, et al.
The Journal of Pediatrics|July 1, 2021
Bloody Diarrhea and Shiga Toxin-Producing Escherichia coli Hemolytic Uremic Syndrome in Children: Data from the ItalKid-HUS NetworkGianluigi Ardissino, Chiara Vignati, Carla Masia, et al.
Journal of Nephrology|May 6, 2021
Kidney transplant in patients with atypical hemolytic uremic syndrome in the anti-C5 era: single-center experience with tailored EculizumabGianluigi Ardissino, Donata Cresseri, Francesca Tel, et al.
Pageof 3